Zemimet SR Dosage/Direction for Use

Dosage of Gemigliptin/Metformin HCl must be individualized on the basis of the patient's current regimen, effectiveness, and tolerability. Gemigliptin/Metformin HCl should generally be administered once daily with a meal in the evening and the dosage should be gradually escalated to reduce the gastrointestinal side effects associated with the metformin component.
Patients taking Gemigliptin/Metformin HCl 50 mg/500 mg or 50 mg/1 g should take one tablet once daily.
Patients taking Gemigliptin/Metformin HCl 25 mg/500 mg or 25 mg/1 g should take two tablets once daily.
The recommended starting dose of Gemigliptin/Metformin HCl in patients who need 50 mg of gemigliptin and who are not currently treated with metformin is 50 mg gemigliptin and 500 mg metformin extended-release once daily with gradual dose escalation to reduce the gastrointestinal side effects due to metformin.
For patients with inadequate glycemic control on metformin monotherapy or for patients with inadequate glycemic control on dual combination of metformin and sulfonylurea or metformin and insulin, the recommended daily dose of Gemigliptin/Metformin HCl is 50 mg gemigliptin and the dose of metformin already being taken. When switching from metformin immediate-release to metformin extended-release, glycemic control should be closely monitored and the dose adjusted on the basis of blood glucose measurements.
When used in combination with a sulfonylurea or insulin, a lower dose of the sulfonylurea or insulin may be required to reduce the risk of hypoglycemia.
For patients switching from co-administration of gemigliptin and metformin, Gemigliptin/Metformin HCl should be initiated at the dose of gemigliptin and metformin already being taken. When switching from metformin immediate release to extended release, glycemic control should be closely monitored and the dose adjusted on the basis of blood glucose measurements.
The maximum recommended daily dose is 50 mg gemigliptin and 2000 mg metformin extended-release.
No studies have been performed specifically examining the safety and efficacy of Gemigliptin/Metformin HCl in patients previously treated with other oral anti-hyperglycemic agents and switched to Gemigliptin/Metformin HCl. Any change in therapy of type 2 diabetes should be undertaken with care and appropriate monitoring as changes in glycemic control can occur.
Gemigliptin/Metformin HCl should be swallowed as a whole and it must not be split, crushed, or chewed before swallowing.